A prospective observational study of evaluating of the effect of denosumab on bone mineral density and biochemical markers of bone turnover in postmenopausal type 2 diabetes women with low bone mass who are intractable to treatment of bisphosphonate or selective estrogen receptor modulator
Not Applicable
- Conditions
- Type 2 diabetes mellitus, Osteoporosis
- Registration Number
- JPRN-UMIN000015136
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
In the group that changed from SERM to Dmab, the LS BMD change rate was significantly increased by 5.0% compared with the group that continued SERM (P <0.04). Serum-bone-specific ALP (BAP) and TRACP-5b were significantly reduced in each group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
We excluded the patients who were satisfied with the following conditions. Pioglitazone or incretin related drugs may be added or adjusted in observational period. HbA1c level is more than 10%. Medications about diabetes mellitus were changed for four weeks before this entry.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone mineral density of femure neck and lumbar spine and biochemical markers of bone turnover
- Secondary Outcome Measures
Name Time Method